Inclusion Criteria

Inclusion:

- Unresectable or metastatic pancreas cancer; participants with previous radical
surgery for pancreas cancer are eligible after progression is documented

- Participants may have received previous adjuvant treatment with gemcitabine with or
without radiotherapy for pancreas cancer

- ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2

- Adequate organ function

- Have an estimated life expectancy of at least 12 weeks and in the judgment of the
investigator, will be able to complete at least 2 cycles of treatment

- Ability to perform the indicated functional performance measures at baseline

Exclusion:

- Prior systemic therapy for unresectable/metastatic pancreas cancer

- Any medical or psychiatric condition, orthopedic or neuromuscular conditions that
could limit participation or confound study results

- Currently taking medications that are considered both muscle building and performance
enhancing (for example, androgen therapies, or anabolic steroids)